Filgotinib for Moderate to Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

The National Institute for Health and Care Excellence (NICE) invited the manufacturer (Gilead) of filgotinib (Jyseleca(TM)), as part of the single technology appraisal process, to submit evidence for its clinical and cost effectiveness for the treatment of patients with moderate to severe rheumatoid...

Descripción completa

Detalles Bibliográficos
Autores principales: Grimm, Sabine E., Wijnen, Ben, Riemsma, Rob, Fayter, Debra, Armstrong, Nigel, Ahmadu, Charlotte, Brandts, Lloyd, Misso, Kate, Kirwan, John R., Kleijnen, Jos, Joore, Manuela A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599377/
https://www.ncbi.nlm.nih.gov/pubmed/34448148
http://dx.doi.org/10.1007/s40273-021-01080-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599377/
https://www.ncbi.nlm.nih.gov/pubmed/34448148
http://dx.doi.org/10.1007/s40273-021-01080-z

Ejemplares similares